BLTE Stock: Price, Earnings History and SEC Filings
Belite Bio, Inc (BLTE) last traded at $154.74, up 2.97% on the latest session and down 8.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.70 against an analyst estimate of $-0.73, a beat of 4.1%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BLTE earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 12, 2026 | $-0.70 | $-0.73 | +4.11% |
| Mar 2026 | May 20, 2026 | $-0.34 | $-0.60 | +43.33% |
| Dec 2025 | Mar 2, 2026 | $-0.38 | $-0.56 | +32.14% |
| Sep 2025 | Nov 10, 2025 | $-0.65 | $-0.53 | -22.64% |
BLTE beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for BLTE
Insider filing activity
BLTE insiders filed 8 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BLTE news
- Belite Bio Uplists to Nasdaq Global Select Market as Retinal Drug Program AdvancesOct 20, 2026 · theglobeandmail.com
- Belite Bio Announces Uplisting to the Nasdaq Global Select MarketOct 19, 2026 · finance.yahoo.com
About Belite Bio, Inc
Belite Bio, Inc (BLTE) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in Cayman Islands. Its fiscal year ends in December.